Literature DB >> 28555420

Limited sampling strategy for predicting busulfan exposure in hematopoietic stem cell transplantation recipients.

Jing-Jing Huang1, Bing Chen1, Jiong Hu2, Wan-Hua Yang3.   

Abstract

Background Optimization of the area under the concentration-time curve (AUC) of busulfan, an essential component of conditioning regimens, improves the outcomes in patients undergoing hematopoietic stem cell transplantation (HSCT). Traditional sampling methods for calculating AUC require multiple sampling. Objective To establish a limited sampling strategy for predicting the AUC0-12 of intravenous busulfan for Chinese adult patients prior to HSCT. Methods The pharmacokinetics of twice-daily intravenous busulfan was studied in forty-five Chinese adult patients. Limited sampling models were established by the multiple linear regression analysis. The prediction error (PE) and the absolute prediction error (APE) were calculated to evaluate predictive accuracy. The agreement between the predicted and actual AUC0-12 was investigated by the Bland-Altman analysis. The accuracy and robustness of the models was validated by the bootstrap analysis. Results The AUC0-12 values of the 1st and 7th doses of busulfan were 1491 ± 403.7 and 1908 ± 518.5 μmol L-1 min, respectively. The 2-sample model suggested that the predicted AUC0-12 of twice-daily intravenous busulfan could be calculated using the following equation: AUC0-12 = 40.017 + 0.955 × C3 + 1.088 × C6 with r2 = 0.919. The mean PE and APE of the model were 0.52 ± 7.67 and 6.32 ± 4.27%, respectively. Conclusion The 2-sample model is an effective and reliable approach to predict the AUC0-12 of twice-daily intravenous busulfan in Chinese adult patients.

Entities:  

Keywords:  Busulfan; Hematopoietic stem cell transplantation; Pharmacokinetics; Sampling strategy

Mesh:

Substances:

Year:  2017        PMID: 28555420     DOI: 10.1007/s11096-017-0481-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  8 in total

1.  A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.

Authors:  William P Vaughan; Delicia Carey; Stephanie Perry; Andrew O Westfall; Donna E Salzman
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

2.  Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?

Authors:  Pamela J Buffery; Kirstie M Allen; Paul K L Chin; Grant A Moore; Murray L Barclay; Evan J Begg
Journal:  Ther Drug Monit       Date:  2014-02       Impact factor: 3.681

3.  Tandem mass spectrometry method for the quantification of serum busulfan.

Authors:  M D Kellogg; T Law; M Sakamoto; N Rifai
Journal:  Ther Drug Monit       Date:  2005-10       Impact factor: 3.681

4.  Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.

Authors:  L Nguyen; F Leger; S Lennon; C Puozzo
Journal:  Cancer Chemother Pharmacol       Date:  2005-08-25       Impact factor: 3.333

5.  Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients.

Authors:  J Yin; Y Xiao; H Zheng; Y C Zhang
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

6.  Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.

Authors:  Hugo F Fernandez; Hai T Tran; Federico Albrecht; Shari Lennon; Humberto Caldera; Mark S Goodman
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

7.  Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Authors:  Borje S Andersson; Ashwin Kashyap; Victor Gian; John R Wingard; Hugo Fernandez; Pablo J Cagnoni; Roy B Jones; Stefano Tarantolo; Wendy W Hu; Karl G Blume; Stephen J Forman; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

Review 8.  Busulfan in hematopoietic stem cell transplant setting.

Authors:  Jeannine S McCune; Leona A Holmberg
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

  8 in total
  1 in total

1.  External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Huiping Huang; Qingxia Liu; Xiaohan Zhang; Helin Xie; Maobai Liu; Nupur Chaphekar; Xuemei Wu
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.